The management of hypogonadism in aging male patients.
This article focuses on the evaluation and management of hypogonadism in aging male patients in the light of recent guidelines. The benefits of treating severe hypogonadism resulting from identifiable pituitary or primary gonadal disease are well established. Milder forms of hypogonadism in the aging male, known as andropause, are common, and constitute an expanding area of clinical interest and research. Several studies indicate that testosterone replacement therapy may produce a wide range of benefits for men with hypogonadism, including improvement in libido, bone density, muscle mass, body composition, mood, and cognition. Currently available data are insufficient to permit a definitive verdict on the balance between risks and benefits of testosterone replacement therapy in aging males.
Sharma
Vishwamitra
V
Research Registrar in Obesity, Luton and Dunstable Hospital, Luton, UK.
Perros
Petros
P
D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000097:blood / Q000502:physiology*; D047649:Andropause / Q000502:physiology; D006062:Gonadotropins / Q000172:deficiency / Q000502:physiology / Q000627:therapeutic use; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D013739:Testosterone / Q000009:adverse effects / Q000172:deficiency* / Q000627:therapeutic use*
D006062:Gonadotropins; D013739:Testosterone